New Century Financial Group LLC Takes Position in The Chemours Company $CC

New Century Financial Group LLC purchased a new position in shares of The Chemours Company (NYSE:CC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 76,035 shares of the specialty chemicals company’s stock, valued at approximately $871,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CC. GAMMA Investing LLC increased its holdings in shares of Chemours by 1,115.2% in the 1st quarter. GAMMA Investing LLC now owns 18,617 shares of the specialty chemicals company’s stock valued at $252,000 after acquiring an additional 17,085 shares during the last quarter. RFG Advisory LLC acquired a new stake in shares of Chemours during the first quarter worth $968,000. Matrix Trust Co grew its position in shares of Chemours by 64.9% during the 1st quarter. Matrix Trust Co now owns 16,408 shares of the specialty chemicals company’s stock valued at $222,000 after buying an additional 6,456 shares during the last quarter. UMB Bank n.a. raised its stake in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock worth $30,000 after acquiring an additional 948 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock worth $30,000 after acquiring an additional 1,444 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Up 2.6%

CC stock opened at $16.33 on Friday. The firm’s 50-day moving average is $14.94 and its two-hundred day moving average is $12.99. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -5.83 and a beta of 1.65. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $22.38. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 15th were given a $0.0875 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.1%. Chemours’s payout ratio is -12.50%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CC. Royal Bank Of Canada lifted their target price on Chemours from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, July 3rd. Mizuho raised their price target on Chemours from $16.00 to $19.00 and gave the stock an “outperform” rating in a report on Tuesday, September 23rd. Truist Financial upped their price objective on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Finally, Zacks Research raised Chemours from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.63.

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $12.06 per share, with a total value of $49,060.08. Following the purchase, the chief executive officer directly owned 191,546 shares of the company’s stock, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.47% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.